INVESTOR ALERT: Investigation of Altimmune, Inc. (ALT) Announced by Holzer & Holzer, LLC

Core Insights - Holzer & Holzer, LLC is investigating whether Altimmune, Inc. complied with federal securities laws following the announcement of topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) [1] - The trial results indicated that there was no statistical significance in improving fibrosis without worsening MASH, leading to a decline in Altimmune's stock price [1] Company Overview - Altimmune, Inc. is a publicly traded company on NASDAQ under the ticker symbol ALT [1] - The company is currently facing scrutiny regarding its compliance with federal securities laws due to the recent trial results [1] Legal Context - Holzer & Holzer, LLC is a law firm that specializes in representing shareholders and investors in litigation, including class action and derivative litigation [3] - The firm has a history of recovering significant amounts for shareholders affected by corporate misconduct [3]